Pharma-Bio Serv Announces Results for the Quarter Ended January 31, 2026

Rhea-AI Summary

Pharma-Bio Serv (OTCQB:PBSV) reported results for the quarter ended January 31, 2026: quarterly revenue of approximately $2.3 million, a year-over-year decrease of about $0.2 million, and net income of $32,860, an improvement of $24,324 versus the same period last year.

Management cited operational efficiency gains, disciplined cost management, and a focus on core markets as drivers of the modest profit and said it aims to build momentum to deliver long-term shareholder value.

Positive

• Net income improved by $24,324 to $32,860 for the quarter
• Company reports a modest profitable quarter after prior period weakness

Negative

• Revenue declined by approximately $0.2 million year-over-year to $2.3 million

News Market Reaction – PBSV

-0.85%

-0.85% Session close to close

In the Mar 18 session, PBSV declined 0.85%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

DORADO, PUERTO RICO / ACCESS Newswire / March 17, 2026 / Pharma-Bio Serv, Inc. ("Pharma-Bio Serv" or the "Company") (OTCQB:PBSV), a compliance, project management and technology transfer support consulting firm that provides services to the pharmaceutical, biotechnology, chemical, medical device, cosmetic, food and allied products industries, today announced that revenues for the quarter ended January 31, 2026 were approximately $2.3 million, a decrease of approximately $0.2 million when compared to the same period last year. Net income for the quarter ended January 31, 2026 was $32,860, an improvement of $24,324 when compared to the same quarter last year.

"We entered this fiscal year focused on executing the strategic priorities established over the past several quarters-sharpening our service portfolio, reinforcing operational alignment, and concentrating on the markets where our capabilities create the most value. We are encouraged by the progress made in improving operational efficiency, which allowed us to deliver a modest profit compared to a slight loss in the same period last year. As we look ahead, we will continue strengthening client relationships, maintaining disciplined cost management, and aligning our organization with the areas of greatest opportunity. We remain confident that these efforts position us well to build momentum and deliver long term value to our shareholders," said Mr. Sanchez, Chief Executive Officer.

About Pharma-Bio Serv, Inc.
Pharma-Bio Serv services the Puerto Rico, United States, Europe and Latin America markets. Pharma-Bio Serv's core business is FDA and international agencies regulatory compliance consulting related services. The Company's global team includes leading engineering and life science professionals, quality assurance managers and directors.

Forward-Looking Statements
This news release contains "forward-looking statements" within the meaning of the U.S. federal securities laws, which statements may include information regarding the plans, intentions, expectations, future financial performance, or future operating performance of Pharma-Bio Serv. Forward-looking statements are based on the expectations, estimates, or projections of management as of the date of this earnings announcement. Although Pharma-Bio Serv's management believes these expectations, estimates, or projections to be reasonable as of the date of this earnings announcement, forward-looking statements are inherently subject to significant business risks, economic uncertainties, and competitive uncertainties, and other factors, which could cause its actual results or performance to differ materially from what may be expressed or implied in the forward-looking statements. Important factors that could cause Pharma-Bio Serv's actual results or performance to differ materially from the forward-looking statements include those set forth in the "Risk Factors" section of Pharma-Bio Serv's Annual Report on Form 10-K for the year ended October 31, 2025, and in its other filings with the Securities and Exchange Commission, which filings are available at www.sec.gov. Pharma-Bio Serv disclaims any intention or obligation to update or revise any forward-looking statements to reflect subsequent events and circumstances, except to the extent required by applicable law.

Company Contact:
Pedro J. Lasanta
Chief Financial Officer
787 278 2709

SOURCE: Pharma-Bio Serv Inc.

View the original press release on ACCESS Newswire

FAQ

What were Pharma-Bio Serv (PBSV) revenues for the quarter ended January 31, 2026?

The company reported approximately $2.3 million in revenue for the quarter. According to the company, this represents a decrease of about $0.2 million versus the same quarter a year earlier, reflecting softer topline activity year-over-year.

How much net income did Pharma-Bio Serv (PBSV) report for Q2 fiscal 2026?

Pharma-Bio Serv reported $32,860 in net income for the quarter. According to the company, that result reflects an improvement of $24,324 compared to the same quarter last year and is tied to operational efficiency gains.

Did Pharma-Bio Serv (PBSV) say why profitability improved in the quarter?

Yes — profitability improved due to operational efficiency and cost discipline. According to the company, management sharpened the service portfolio and aligned operations to focus on higher-value markets and clients.

Does the Pharma-Bio Serv (PBSV) announcement include guidance or forward-looking financial targets?

No specific numeric guidance was provided in the release. According to the company, leadership emphasized continued focus on client relationships, cost management, and aligning resources to areas of opportunity instead of issuing guidance.

What does the revenue decline mean for Pharma-Bio Serv (PBSV) shareholders?

Revenue was down about $0.2 million year-over-year, which may temper near-term growth expectations. According to the company, management expects efficiency and client focus to help rebuild momentum over time.

How did Pharma-Bio Serv (PBSV) describe its strategic priorities for fiscal 2026?

The company emphasized sharpening its service portfolio, reinforcing operational alignment, and focusing on core markets. According to the company, these priorities aim to improve efficiency and position the firm to deliver long-term shareholder value.